Myelodysplastic Syndromes, Version 2.2015

被引：31

作者：

Greenberg, Peter L. ^{[1
]}

Stone, Richard M. ^{[2
]}

Bejar, Rafael ^{[3
]}

Bennett, John M. ^{[4
]}

Bloomfield, Clara D. ^{[5
,6
]}

Borate, Uma ^{[7
]}

De Castro, Carlos M. ^{[8
]}

Deeg, H. Joachim ^{[9
]}

DeZern, Amy E. ^{[10
]}

Fathi, Amir T. ^{[11
]}

Frankfurt, Olga ^{[12
]}

Gaensler, Karin ^{[13
]}

Garcia-Manero, Guillermo ^{[14
]}

Griffiths, Elizabeth A. ^{[15
]}

Head, David ^{[16
]}

Klimek, Virginia ^{[17
]}

Komrokji, Rami ^{[18
]}

Kujawski, Lisa A. ^{[19
]}

Maness, Lori J. ^{[20
]}

O'Donnell, Margaret R. ^{[21
]}

Pollyea, Daniel A. ^{[22
]}

Scott, Bart ^{[9
]}

Shami, Paul J. ^{[23
]}

Stein, Brady L. ^{[12
]}

Westervelt, Peter ^{[24
,25
]}

Wheeler, Benton ^{[26
]}

Shead, Dorothy A. ^{[27
]}

Smith, Courtney ^{[27
]}

机构：

[1] Stanford Canc Inst, Stanford, CA 94305 USA

[2] Dana FarberBrigham & Womens Canc Ctr, Boston, MA 02115 USA

[3] Univ Calif San Diego, Moores Canc Ctr, San Diego, CA USA

[4] Univ Rochester, Med Ctr, Rochester, NY 14627 USA

[5] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Columbus, OH 43210 USA

[6] Solove Res Inst, Columbus, OH USA

[7] Univ Alabama, Birmingham Comprehens Canc Ctr, Tuscaloosa, AL 35487 USA

[8] Duke Canc Inst, Durham, NC USA

[9] Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, Seattle, WA USA

[10] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA

[11] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA

[12] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA

[13] UCSF, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[14] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[15] Roswell Pk Canc Inst, Buffalo, NY USA

[16] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[17] Mem Sloan Kettering Canc Ctr, New York, NY USA

[18] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[19] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA

[20] Fred & Pamela Buffett Canc Ctr, Omaha, NE USA

[21] City Hope Comprehens Canc Ctr, Duarte, CA USA

[22] Univ Colorado, Ctr Canc, Boulder, CO 80309 USA

[23] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA

[24] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO USA

[25] Washington Univ, Sch Med, St Louis, MO 63130 USA

[26] Univ Tennessee, St Jude Childrens Res Hosp, Ctr Hlth Sci, Knoxville, TN 37996 USA

[27] Natl Comprehens Canc Network, Ft Washington, PA USA

来源：

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2015年 / 13卷 / 03期

关键词：

PROGNOSTIC SCORING SYSTEM; TRANSFUSION-DEPENDENT PATIENTS; CLINICAL-PRACTICE GUIDELINE; BLOOD-CELL TRANSFUSION; ACUTE MYELOID-LEUKEMIA; SETBP1; MUTATIONS; LOWER-RISK; LENALIDOMIDE; VALIDATION; EVOLUTION;

D O I：

10.6004/jnccn.2015.0038

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The NCCN Guidelines for Myelodysplastic Syndromes (MDS) comprise a heterogeneous group of myeloid disorders with a highly variable disease course that depends largely on risk factors. Risk evaluation is therefore a critical component of decision-making in the treatment of MDS. The development of newer treatments and the refinement of current treatment modalities are designed to improve patient outcomes and reduce side effects. These NCCN Guidelines Insights focus on the recent updates to the guidelines, which include the incorporation of a revised prognostic scoring system, addition of molecular abnormalities associated with MDS, and refinement of treatment options involving a discussion of cost of care.

引用

页码：261 / 272

页数：12

共 50 条

[41] Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications
Stahl, Maximilian
Zeidan, Amer M.
CANCER, 2017, 123 (10) : 1703 - 1713
[42] Myelodysplastic syndromes in children
Galaverna, Federica
Ruggeri, Annalisa
Locatelli, Franco
CURRENT OPINION IN ONCOLOGY, 2018, 30 (06) : 402 - 408
[43] Overview of Myelodysplastic Syndromes
Beris, Photis
Georgiou, George
SEMINARS IN HEMATOLOGY, 2012, 49 (04) : 287 - 294
[44] Myelodysplastic syndromes: a review of therapeutic progress over the past 10 years
Feld, Jonathan
Belasen, Abigail
Navada, Shyamala C.
EXPERT REVIEW OF ANTICANCER THERAPY, 2020, 20 (06) : 465 - 482
[45] Progress in Myelodysplastic Syndromes
Garcia-Manero, Guillermo
CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S286 - S292
[46] Clofarabine for myelodysplastic syndromes
Tiu, Ramon V.
Traina, Fabiola
Sekeres, Mikkael A.
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2011, 20 (07) : 1005 - 1014
[47] Pharmacotherapy of myelodysplastic syndromes
Galili, Naomi
Raza, Azra
EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (11) : 1889 - 1899
[48] Epigenetics of myelodysplastic syndromes
Itzykson, R.
Fenaux, P.
LEUKEMIA, 2014, 28 (03) : 497 - 506
[49] Epigenetics in myelodysplastic syndromes
Heuser, Michael
Yun, Haiyang
Thol, Felicitas
SEMINARS IN CANCER BIOLOGY, 2018, 51 : 170 - 179
[50] Pediatric myelodysplastic syndromes
Hofmann, Inga
JOURNAL OF HEMATOPATHOLOGY, 2015, 8 (03) : 127 - 141

← 1 2 3 4 5 →